PCRX Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of 2.85% compared to Pacira BioSciences's net margin of --. Pacira BioSciences's return on equity of -12.66% beat Edgewise Therapeutics's return on equity of --.

Pacira BioSciences has a consensus price target of $30.40, signalling upside risk potential of 19.59%. On the other hand Edgewise Therapeutics has an analysts' consensus of $39.00 which suggests that it could grow by 155.57%. Given that Edgewise Therapeutics has higher upside potential than Pacira BioSciences, analysts believe Edgewise Therapeutics is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.518, which suggesting that the stock is 48.161% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $168.9M, which are larger than Edgewise Therapeutics quarterly revenues of --. Pacira BioSciences's net income of $4.8M is higher than Edgewise Therapeutics's net income of -$40.8M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.71x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 2.85% compared to Pacira BioSciences's net margin of 26.7%. Pacira BioSciences's return on equity of -12.66% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Pacira BioSciences has a consensus price target of $30.40, signalling upside risk potential of 19.59%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $730.05 which suggests that it could grow by 49.61%. Given that Regeneron Pharmaceuticals has higher upside potential than Pacira BioSciences, analysts believe Regeneron Pharmaceuticals is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.518, which suggesting that the stock is 48.161% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.36% to investors and pays a quarterly dividend of $0.88 per share. Pacira BioSciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $168.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Pacira BioSciences's net income of $4.8M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Regeneron Pharmaceuticals's PE ratio is 12.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.71x versus 4.00x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 2.85% compared to Pacira BioSciences's net margin of -60.08%. Pacira BioSciences's return on equity of -12.66% beat Sarepta Therapeutics's return on equity of -20.94%.

Pacira BioSciences has a consensus price target of $30.40, signalling upside risk potential of 19.59%. On the other hand Sarepta Therapeutics has an analysts' consensus of $89.96 which suggests that it could grow by 109.16%. Given that Sarepta Therapeutics has higher upside potential than Pacira BioSciences, analysts believe Sarepta Therapeutics is more attractive than Pacira BioSciences.

Pacira BioSciences has a beta of 0.518, which suggesting that the stock is 48.161% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $168.9M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Pacira BioSciences's net income of $4.8M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.71x versus 2.14x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 2.85% compared to Pacira BioSciences's net margin of 23.33%. Pacira BioSciences's return on equity of -12.66% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Pacira BioSciences has a consensus price target of $30.40, signalling upside risk potential of 19.59%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 11.02%. Given that Pacira BioSciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Pacira BioSciences is more attractive than Vertex Pharmaceuticals.

Pacira BioSciences has a beta of 0.518, which suggesting that the stock is 48.161% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

Pacira BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira BioSciences pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Pacira BioSciences quarterly revenues are $168.9M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Pacira BioSciences's net income of $4.8M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Pacira BioSciences's price-to-earnings ratio is 11.70x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira BioSciences is 1.71x versus 10.51x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.